DOUBLE BLIND, RANDOMIZED, MULTICENTER, PLACEBO CONTROLLED PARALLEL AND ACTIVE CONTROLLER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0767 IN THE ALTERATION OF GLUCOSE AND LIPIDS IN PATIENTS THAT HAVE TYPE 2 DIABETES.
Phase 1
- Conditions
- -E149 Unspecified diabetes mellitus, without complicationsUnspecified diabetes mellitus, without complicationsE149
- Registration Number
- PER-006-03
- Lead Sponsor
- MERCK SHARP & DOHME PERU S.R.L.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. End the initial double-blind study.
2. Have met> 75% of study medication during the double-blind period of the baseline study.
3. Understanding of study procedures and agreement to participate in the study granting written informed consent.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method